C12N 2770/36161
Methods of inactivation or attenuation
C12N2770/36161 (Methods of inactivation or attenuation) appears on 81 US grants and 87 published applications in this corpus.
Search patents in C12N- Granted patents
- 81
- Published applications
- 87
- Assignees
- 49
- Inventors
- 147
- Latest grant
- 23 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 2 |
| 2002 | 7 | 3 |
| 2003 | 7 | 7 |
| 2004 | 1 | 8 |
| 2005 | 0 | 2 |
| 2006 | 7 | 5 |
| 2007 | 3 | 2 |
| 2008 | 5 | 6 |
| 2009 | 2 | 2 |
| 2010 | 3 | 2 |
| 2011 | 1 | 5 |
| 2012 | 0 | 2 |
| 2013 | 4 | 2 |
| 2014 | 3 | 6 |
| 2015 | 2 | 3 |
| 2016 | 2 | 2 |
| 2017 | 2 | 3 |
| 2018 | 1 | 1 |
| 2019 | 1 | 4 |
| 2020 | 5 | 2 |
| 2021 | 3 | 3 |
| 2022 | 0 | 4 |
| 2023 | 3 | 3 |
| 2024 | 1 | 4 |
| 2025 | 1 | 3 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production23 Sep 2025US 12,419,947 B2Najit Technologies, Inc.
- Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process1 Oct 2024US 12,102,676 B2Najit Technologies, Inc.
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production19 Dec 2023US 11,844,832 B2Najit Technologies, Inc.
- Compositions and methods for the prevention and treatment of rabies virus infection22 Aug 2023US 11,730,804 B1Replicate Bioscience, Inc.
- Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process25 Apr 2023US 11,633,470 B2Najit Technologies, Inc.
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy2 Jul 2026US 2026/0183354 A2SunVax mRNA Therapeutics Inc.
- Alphavirus (Mayaro virus) Constructs Attenuated for Human and Method of its Use18 Dec 2025US 2025/0381263 A1Institut Pasteur de Montevideo
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy11 Sep 2025US 2025/0281557 A1SunVax mRNA Therapeutics Inc.
- Compositions and methods for the prevention and treatment of rabies virus infection12 Jun 2025US 2025/0186574 A1Replicate Bioscience, Inc.
- Attenuated alphavirus28 Nov 2024US 2024/0390476 A1Zoetis Services LLC
Most cited
By later US patents
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994
- Recombinant plant viral nucleic acids105US 5,589,367 ABiosource Technologies, Inc. · 1996
- Alphavirus RNA replicon systems100US 5,792,462 AThe United States of America as represented by the Secretary of the Army · 1998
- Recombinant plant viral nucleic acids86US 5,866,785 ABiosource Technologies, Inc. · 1999
- Alphavirus RNA replicon systems77US 6,156,558 AThe University of North Carolina at Chapel Hill · 2000